Medication info

Ibanel Injection (Sodium Ibandronate Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Kujoo Pharmaceutical Co., Ltd.
Appearance
A colorless, clear liquid in a colorless transparent prefilled syringe with a single-use syringe attached.
Packaging
5 prefilled syringes/box [3ml/prefilled syringe], 1 prefilled syringe/box [3ml/prefilled syringe]
Approval status
Active

MFDS item code 201306406 · Approved 2013.03.22 · Insurance code 669804231

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should also take calcium and vitamin D. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is required. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Since clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, administration of this medicine is not recommended. Elderly patients No dosage adjustment is required.
Child administration
Efficacy and safety in children 18 years of age or younger have not been studied.

Ingredients

Manufacturer
Kujoo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis, which is common in postmenopausal women. Osteoporosis is a condition where bones become weak and are prone to fractures; this medication helps increase bone strength and reduce the risk of fractures. Thus, it helps postmenopausal women maintain healthy bones.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should also take calcium and vitamin D. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is required. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Since clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, administration of this medicine is not recommended. Elderly patients No dosage adjustment is required.

Child administration

Efficacy and safety in children 18 years of age or younger have not been studied.

Precautions

This medication should only be administered intravenously, as improper injection into arteries or surrounding veins can cause tissue damage. Patients with allergies to this medication or its components, or those with untreated hypocalcemia, should not use this medication. While taking this medication, gastrointestinal symptoms such as indigestion, abdominal pain, nausea, diarrhea, constipation, as well as adverse reactions like muscle pain, joint pain, headache, and rash may occur. Some patients may experience flu-like symptoms such as fever, myalgia, fatigue, and chills, but these are generally mild and resolve without treatment. This medication may temporarily lower serum calcium levels; therefore, hypocalcemia or bone and mineral metabolism disorders must be treated before administration. During treatment, adequate intake of calcium and vitamin D is important, and supplements should be taken if necessary. Serious side effects of osteonecrosis of the jaw have been reported, so it is advisable to have a dental examination before administration and to avoid excessive dental treatment during therapy. The risk of osteonecrosis is particularly high for cancer patients, steroid users, or those with poor oral hygiene, requiring caution. Rarely, cases of necrosis of the bone around the ear have been reported among patients who received this medication, so if there is ear pain or discharge, medical consultation should be sought immediately. Patients who have used this medication long term may experience atypical fractures in the femur or other bones, and if there is pain in the thigh or groin area, evaluation is recommended. Severe allergic reactions or anaphylaxis may occur during treatment, so it is imperative to stop administration and seek emergency treatment if symptoms arise. Women who are pregnant or breastfeeding should preferably avoid this medication as its safety has not been established. This medication is excreted by the kidneys, so patients with renal impairment should be regularly monitored while using it. In cases of overdose, renal and hepatic toxicity may occur, therefore careful observation of renal and liver function should be conducted if overdose is suspected. This medication should not be mixed with solutions containing calcium and must be administered only via intravenous injection. Syringes and needles should not be reused and must be disposed of safely after use.

Side effects

  • Gastritis
  • diarrhea
  • abdominal pain
  • indigestion
  • nausea
  • constipation
  • musculoskeletal pain
  • joint pain
  • muscle pain
  • influenza-like illness
Show 27 more
  • fatigue
  • headache
  • rash
  • bone pain
  • weakness
  • injection site reaction
  • phlebitis
  • thrombophlebitis
  • hypersensitivity reaction
  • angioedema
  • facial swelling
  • edema
  • urticaria
  • uveitis
  • episcleritis
  • scleritis
  • anaphylactic reaction
  • shock
  • asthma exacerbation
  • Stevens-Johnson syndrome
  • erythema multiforme
  • vesicular dermatitis
  • atypical femoral fracture
  • subtrochanteric femoral fracture
  • external auditory canal osteonecrosis
  • acute kidney failure
  • sensory loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture ingress, at a temperature between 1 and 30 degrees Celsius. Proper storage will maintain the medication's efficacy and prevent deterioration.

Appearance and packaging

Appearance

A colorless, clear liquid in a colorless transparent prefilled syringe with a single-use syringe attached.

Package unit

5 prefilled syringes/box [3ml/prefilled syringe], 1 prefilled syringe/box [3ml/prefilled syringe]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.